Also known as: CF
Cystic fibrosis is a progressive inherited genetic disorder that affects the lungs, pancreas, and other organs. It is caused by mutations in the CFTR gene that lead to abnormal ion transport and thick, sticky mucus in multiple organs. The disease is chronic and requires long-term multidisciplinary management.
New research shows that many people with disease-causing gene mutations never develop illness, challenging traditional assumptions. Studies of 'modifier genes' and genetic outliers are revealing how some individuals stay healthy, potentially leading to new treatments for genetic diseases.
New investment models and digital twin technologies are bridging gaps in rare disease drug development, where traditional funding and trial designs fall short. Patient-led funding and family offices provide capital, while regulators accept digital evidence to accelerate therapies for the more than 7,000 rare diseases with few approved treatments.
4D Molecular Therapeutics (Nasdaq: FDMT) granted a total of 229,700 restricted stock units to 20 new non-executive hires across three awards in 2026 under its Employment Inducement Award Plan. The grants occurred on February 10, April 14, and July 14, as part of Nasdaq-compliant inducement awards.
Vertex Pharmaceuticals dominates cystic fibrosis therapies with TRIKAFTA/KAFTRIO generating $2.57 billion in Q4 2025 and ALYFTREK ramping to $380.1 million. The company posted strong free cash flow of $3.19 billion in 2025 and is expanding into pain, kidney disease, and gene-editing therapies.
Researchers report advances in RNA-based gene therapy: an FDA-approved small molecule modulates RNA splicing, protein-coated nanoparticles enable safer delivery, and a microRNA platform targets glioblastoma.
Vertex secured a Germany reimbursement agreement for CASGEVY and signed a WuXi Biologics pact for a preclinical autoimmune T-cell engager. The moves add to efforts to build revenue beyond cystic fibrosis.
Vertex completed the rolling BLA submission for povetacicept in IgA nephropathy after positive Phase 3 RAINIER interim data. The company plans to use a Priority Review Voucher to accelerate FDA review.
Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.
Researchers developed a lipid nanoparticle gene-editing approach that inserted a full CFTR gene into airway cells and restored 88% to 100% of normal channel function in a cystic fibrosis lab model.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07519460 |
Effects of High-Frequency Chest Wall Oscillation Combined With Concurrent Training on Cough,in Cystic Fibrosis Patients |
NOT_YET_RECRUITING | NA |
| NCT07500493 |
Tele-Rehabilitation in Adults With Cystic Fibrosis |
NOT_YET_RECRUITING | NA |
| NCT07485543 |
Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07437105 |
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07414810 |
Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function |
NOT_YET_RECRUITING | NA |
| NCT07349394 |
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants |
COMPLETED | PHASE1 |
| NCT07342920 |
Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis |
RECRUITING | |
| NCT07283770 |
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07274631 |
A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine |
RECRUITING | |
| NCT07088614 |
Effectiveness of Respiratory Physiotherapy on Frequency of Exacerbations, Lung Function and Quality of Life After 6 Months in Children With Cystic Fibrosis |
COMPLETED | NA |
